Revolutionizing Multiomics Research: Waters' New Xevo MRT P10 Mass Spectrometer Unleashed

Introducing the Waters Xevo MRT P10 Mass Spectrometer

In a significant advancement for the scientific community, Waters Corporation has unveiled its new Xevo MRT P10 Mass Spectrometer at the 74th ASMS Conference on Mass Spectrometry and Allied Topics. This cutting-edge high-resolution system promises to revolutionize multiomics research, enabling unprecedented sensitivity and speed that will empower researchers in their quests for deeper biological insights.

Unmatched Sensitivity and Speed

The Xevo MRT P10 MS boasts an incredible enhancement in MS/MS sensitivity — up to 20 times higher than previous models. This improvement, coupled with a twofold increase in acquisition speeds, provides scientists with the tools needed to explore complex biological samples with remarkable accuracy. Such efficiency is crucial for next-generation multiomics, therapeutic, and high-throughput workflows, allowing for more comprehensive data in less time.

James Hallam, Vice President and General Manager of Liquid Chromatography-Mass Spectrometry at Waters Corporation, emphasized the benefits of the new system: "By combining enhanced sensitivity with the fastest acquisition speeds in the industry, this platform enables researchers to see more of the biology and make confident decisions. The Xevo MRT P10 MS is a powerful advancement for our customers aiming to enhance multiomics research and develop life-changing therapies."

A Leap Forward in Lipidomics

This innovative system is particularly poised to advance studies in lipidomics. The Xevo MRT P10 can identify up to 40% more lipids via LC‑MS/MS compared to leading competitors, greatly enhancing the capacity for researchers to dissect complex biological pathways and understand disease mechanisms.

The integration of the DESI XS source further distinguishes the Xevo MRT P10 in high-resolution spatial analysis, allowing for a sixfold increase in throughput and delivering higher-confidence results in studies evaluating disease and treatment responses. With such capabilities, researchers can generate superior data quality while seamlessly processing a larger volume of samples.

Supporting Diverse Research Applications

The versatility of the Xevo MRT P10 MSS places it at the forefront of various research applications, including proteomics and biopharmaceutical analysis. Researchers at institutions like Colorado State University have highlighted how the system responds adeptly to complex disease inquiries, underlining its potential for deep proteomic discovery. With sub-ppm mass accuracy and new acquisition modes, the system ensures that even closely related signals can be separated efficiently — an essential requirement for characterizing biological biomarkers.

Availability and Future Impact

Scheduled for global release in summer 2026, the Xevo MRT P10 MS is expected to set a new standard in the realm of mass spectrometry. As research demands continue to evolve, the platform's high-throughput capabilities will be vital in accelerating biomarker identification and the validation of therapeutic targets, offering researchers unprecedented levels of insight within their studies. For those interested in exploring the capability of the Xevo MRT P10 MS, Waters Corporation invites inquiries and demonstrations via their product page.

By advancing the frontiers of mass spectrometry, the Xevo MRT P10 stands as a testament to Waters Corporation's commitment to supporting groundbreaking research that enhances our knowledge of health and disease, ultimately leading to improved patient outcomes and innovative therapeutic strategies.